Antihypertensive activity of angiotensin II AT1 receptor antagonists: A systematic review of studies with 24 h ambulatory blood pressure monitoring

Journal of Hypertension

Volumn 25, Issue 7, 2007, Pages 1327-1336

  Fabia, Maria Jose ^a   Abdilla, Noelia ^a   Oltra, Rosa ^a   Fernandez, Conrado ^a   Redon, Josep ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Ambulatory blood pressure monitoring; Amlodipine; Angiotensin receptor blockers; Candesartan; Enalapril; Eprosartan and olmesartan; Irbesartan; Losartan; Telmisartan; Valsartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PLACEBO; TELMISARTAN; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERTENSION; MEDLINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 34250370923     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3280825625     Document Type: Review

References (76)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
2. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
3. Weber MA. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens 1999; 12:189S-194S.
4. Birkenhager WH, de Leuw PW. Non-peptide angiotensin type I receptor antagonists in the treatment of hypertension. J Hypertens 1999; 17:873-881.
5. Neutel JM. Safety and efficacy of angiotensin II receptor antagonists. Am J Cardiol 1999; 84:13K-17K.
6. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion J-M, Mancia G, et al., on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21:821-848.
7. Redon J. The normal circadian pattern of blood pressure: implications for treatment. Int J Clin Pract 2004; 145 (Suppl.):3-8.
8. Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004; 26:A33-A37.
9. De la Sierra A, Gil-Extremera B, Calvo C, Campo C, García-Puig J, Márquez E, et al. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/ hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. J Hum Hypertens 2004; 18:215-222.
10. Smith DHG, Cramer MM, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of tiration-to-response studies. Blood Press Monit 2003; 8:111-117.
11. Neutel JM, Kolloch RE, Plouin PF, Meinicke TW, Schumacher H. Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. A randomised ABPM study. J Hum Hypertens 2003; 17:569-575.
12. Neutel JM, Smith DHG. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens 2003; 5:58-63.
13. Okuguchi T, Osanai T, Fujiwara N, Kato T, Metoki N, Konta Y, Okumura K. Effects of losartan on nocturnal blood pressure in patients with stroke: comparison with angiotensin converting enzyme inhibitor. Am J Hypertens 2002; 15:998-1002.
14. White WB, Sica DA, Calhoun D, Mansoor GA, Anders RJ. Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Am Heart J 2002; 144:657-665.
15. Ishimitsu T, Minami J, Yoshii M, Suzuki T, Inada H, Ohta S, et al. Comparison of the effects of amlodipine and losartan on 24-hour ambulatory blood pressure in hypertensive patients. Clin Exp Hypertens 2002; 24:41-50.
16. Bakris G, Sica D, Ram V, Fagan T, Vaitkus PT, Anders RJ. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens 2002; 15:53-57.
17. Nakao N, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M. Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressure in non-diabetic renal disease: A cooperate-ABP substudy. Am J Nephrol 2004; 24:543-548.
18. Rossing K, Christensen PK, Andersen S, Hovind P, Hansen HP, Parving H. Comparative effects of irbesartan on ambulatory and office blood pressure. Diabetes Care 2003; 26:569-574.
19. Cupisti A, Rizza GM, D'Alessandro C, Morelli E, Barsotti G. Effects of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients. Biomed Pharmacother 2003; 57:169-172.
20. MacGregor GA, Viskoper JR, Antonios TF, He FJ. Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. Hypertension 2000; 36:454-460.
21. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62:1345-1353.
22. Lacourcière Y, Krzesinski J, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9:203-210.
23. Mancia G, Korlipara K, Rossum P, Villa G, Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7:135-142.
24. White WB, Lacourcière Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Am J Hypertens 2004; 17:347-353.
25. Palatini P, Malacco E, Di Somma S, Carretta R, Dorigatti F, Bertocchi F, Mann J. Trough : peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amoldipine. Eur J Clin Pharmacol 2002; 57:765-770.
26. Smith DHG, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy. A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5:41-50.
27. Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. Am J Hypertens 1999; 12:1181-1187.
28. White WB, McCabe EJ, Mansoor GA. Comparison of office and ambulatory blood pressure measurements to assess the angiotensin II receptor antagonist eprosartan. Blood Press Monit 1996; 1:45-50.
29. Radauceanu A, Boivin J, Bernaud C, Fay R, Zannad F, and the CIC General Practitioners Investigators' Group. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol. Fundam Clin Pharmacol 2004; 18:483-491.
30. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil evaluated by means of ambulatory monitoring of arterial blood pressure over 24 h in patients with arterial hypertension. [in Spanish]. Clin Drug Invest 2003; 23:419-430.
31. Palatini P, Mugellini A, Spagnuolo V, Santonastaso M, Ambrosio GB, Caiazza A, Malacco E, on behalf of the Investigators Group. Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension. Blood Press Monit 2004; 9:91-97.
32. White WB, Anwar YA, Mansoor GA, Sica DA. Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension. Am J Hypertens 2001; 14:1248-1255.
33. Oparil S. Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists. J Hum Hypertens 2002; 16 (Suppl. 2):S17-S23.
34. Coca A, Sobrino J, Soler J, Felip A, Pelegrí A, Mínguez A, et al. Trough-topeak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. J Cardiovasc Pharmacol 2002; 39:824-833.
35. Howe P, Phillips P, Saini R, Kassler-Taub K. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Clin Exp Hypertens 1999; 21:1373-1396.
36. Coca A, Calvo C, Sobrino J, Gómez E, López-Paz JE, Sierra C, et al. Once-daily fixex-combination irbesartan 300 mg/hydrochlorothiazide 25mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther 2003; 25:2849-2864.
37. Mancia G, Dell'Oro R, Turri C, Grassi G. Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. Am J Cardiol 1999; 84:28S-34S.
38. Zanchetti A, Omboni S. Comparison of candesartan versus enalapril in essential hypertension. Am J Hypertens 2001; 14:129-134.
39. Malacco E, Piazza S, Scandiani L, Zoppi A. Effects of valsartan/hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients. Adv Ther 2004; 21:149-161.
40. Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19 (Suppl. 1):S41-S48.
41. Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 2003; 42:283-290.
42. Poirier L, De Champlain J, Larochelle P, Lamarre-Cliche M, Lacourciè re Y. A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension. Blood Press Monit 2004; 9:231-236.
43. Eguchi K, Kario K, Shimada K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am J Cardiol 2003; 92:621-624.
44. Eguchi K, Kario K, Hoshide Y, Hoshide S, Ishikawa J, Morinari M, et al. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. Am J Hypertens 2004; 17:112-117.
45. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17:425-432.
46. Nalbantgil I, Nalbantgil S, Özerkan F, Yilmaz H, Gürgün C, Zoghi M, et al. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension. Int J Clin Pract 2004; 58:50-54.
47. Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80mg and valsartan 160mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004; 22:837-846.
48. Parra Carrillo JZ, Fernández M, Barrera M, Bahena J, Estrella M, Olivares Ruiz R, et al. Effect of telmisartan 80mg once daily on 24-h blood pressure profile in patients with mid-to-moderate hypertension failing to respond to prior antihypertensive therapy. Int J Clin Pract Suppl 2004; 145:9-15.
49. Lacourcière Y, Poirier L. Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Am J Hypertens 2003; 16:1036-1042.
50. Himmelmann A, Keinänen-Kiukaanniemi S, Wester A, Redón J, Asmar R, Hedner T. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press 2001; 10:43-51.
51. Ding PY-A, Chu K-M, Chiang H-T, Shu K-H. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40mg in comparison with losartan 50mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl 2004; 145:16-22.
52. Asmar R, Lacourcière Y. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. J Hypertens 2000; 18:1683-1690.
53. Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens Suppl 2003; 21:S43-S46.
54. Amerena J, Pappas S, Ouellet J-P, Williams L, O'Shaughnessy D. ABPM comparison of the antihypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res 2002; 30:543-552.
55. Monterroso VH, Rodríguez V, Carbajal ET, Vogel DR, Aroca GJ, García LH, et al. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Adv Ther 2000; 17:117-131.
56. Phillips RA, Kloner RA, Grimm RH, Weinberger M. The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. J Clin Hypertens 2003; 5:17-23.
57. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3:283-291.
58. Bakris G. Comparison of telmisartan versus valsartan in the treatment of midl to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens 2002; 4 (Suppl. 1):26-31.
59. Neutel JM, Elliot WJ, Izzo JL, Chen CL, Masonson HN. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens 2002; 4:325-331.
60. Neutel JM. Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker telmisartan. Blood Press 2001; 10 (Suppl.):27-32.
61. Neutel JM. Use of ambulatory blood pressure monitoring to evaluate the selective angiotensin II receptor antagonist, telmisartan, and other antihypertensive drugs. Blood Press Monit 2000; 5 (Suppl. 1):S35-S40.
62. Palatini P, Dorigatti F, Mugellini A, Spagnuolo V, Var N, Ferrara R, Bertocchi F. Ambulatory versus clinic blood pressure for the assessment of antihypertensive efficacy in clinical trials: insights from the Val-Syst Study. Clin Ther 2004; 26:1436-1445.
63. Stergiou GS, Efstathiou SP, Skeva II, Baibas NM, Roussias LG, Mountokalakis TD. Comparison of the smoothness index, the trough : peak ratio and the morning : evening ratio in assessing the features of the antihypertensive drug effect. J Hypertens 2003; 21:913-920.
64. Stergiou GS, Efstathiou SP, Skeva II, Baibas NM, Kalkana CB, Mountokalakis TD. Assessment of drug effects on blood pressure and pulse pressure using clinic, home and ambulatory measurements. J Hum Hypertens 2002; 16:729-735.
65. Lacourciére Y, Gil-Extremera B, Mueller O, Byrne M, Williams L. Efficacy and tolerability of fixed-dose combinations of telmisartan plus hydrochlorothiazide compared with losartan plus hydrochlorothiazide in patients with essential hypertension. Int J Clin Pract 2003; 57:273-279.
66. Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomised, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16:1123-1132.
67. Coca A, Calvo C, García-Puig J, Gil-Extremera B, Aguilera MT, De la Sierra A, et al. A multicenter, randomised, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MBPAVEL Study. Clin Ther 2002; 24:126-138.
68. Fogari R, Ambrosoli S, Corradi L, Esposti ED, Mos L, Nami R, et al. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15:1511-1518.
69. Heuer HJ, Schöndorfer G, Högemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl. 2):S55-S56.
70. Fogari R, Preti P, Zoppi A, Corradi L, Pasotti C, Rinaldi A, Mugellini A. Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation. Am J Hypertens 2005; 18:577-583.
71. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15:206-217.
72. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15:229-240.
73. Mallion JM, Siche JP, Lacourcière Y, and the Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13:657-664.
74. Neutel J, Weber M, Pool J, Smith D, Fitzsimmons S, Chiang Y, Gatlin M. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997; 19:447-458.
75. Lacourcière Y, Lenis J, Orchard R, Lewarczuk R, Houde M, Pesant Y, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3:295-302.
76. Chen PY, Popovich PM. Correlation: parametric and nonparametric measures. Newbury Park, CA: Sage Publications, Inc.; 2002.